PT  - JOURNAL ARTICLE
AU  - L. Bingle
AU  - T. D. Tetley
TI  - Secretory leukoprotease inhibitor: partnering alpha 1-proteinase inhibitor to combat pulmonary inflammation.
AID  - 10.1136/thx.51.12.1273
DP  - 1996 Dec 01
TA  - Thorax
PG  - 1273--1274
VI  - 51
IP  - 12
4099  - http://thorax.bmj.com/content/51/12/1273.short
4100  - http://thorax.bmj.com/content/51/12/1273.full
SO  - Thorax1996 Dec 01; 51
AB  - Secretory leukoprotease inhibitor (SLPI) is a low molecular weight serine proteinase inhibitor, notably of neutrophil elastase (NE), which is synthesised and secreted by the pulmonary epithelium. SLPI plays an important role in limiting NE-induced pulmonary inflammation and, significantly, it also possesses anti-HIV activity. SLPI is a significant component of the anti-NE shield in the lung which has different reactivity from, and is therefore complementary to, the anti-NE action of alpha 1-proteinase inhibitor (alpha 1-PI). Inhaled recombinant SLPI (rSLPI) could prove beneficial in partnership with alpha 1-PI in the treatment of a number of inflammatory lung disorders including emphysema, chronic bronchitis, cystic fibrosis, and adult respiratory distress syndrome.